Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia - Test2 - elhamkhani - TriplyDB

Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia

Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia

http://www.wikidata.org/entity/Q33861150

about

Safety and efficacy of azacitidine in myelodysplastic syndromes Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations Cancer stem cells: relevance to clinical transplantation Current and emerging strategies for the prevention of graft-versus-host disease Clinical Results of Hypomethylating Agents in AML Treatment Evaluation of BM cytomorphology after allo-SCT in patients with AML.Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study.Platelet recovery before allogeneic stem cell transplantation predicts posttransplantation outcomes in patients with acute myelogenous leukemia and myelodysplastic syndrome.Unrelated donor transplantation for acute myelogenous leukemia in first remission Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.Challenges in treating older patients with acute myeloid leukemia.Decitabine in the treatment of myelodysplastic syndromes.Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantatio Targeting DNA methylation for epigenetic therapy.Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission.Minimal residual disease following allogeneic hematopoietic stem cell transplantation.Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation.Blood and marrow transplant clinical trials network state of the Science Symposium 2014 In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available?Emerging therapies in hematopoietic stem cell transplantation Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.Transplantation for myelodysplastic syndrome in the era of hypomethylating agents.Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome.Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation.An overview of epigenetics in nursing Hypomethylating agents after allogeneic blood stem cell transplantation.Relapse after allogeneic stem cell transplantation Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia.Epigenomics in hematopoietic transplantation: novel treatment strategies.Advances in conditioning regimens for older adults undergoing allogeneic stem cell transplantation to treat hematologic malignancies.

P2860

Q24596561-9DF05E7A-7BA7-4ED3-AE5F-2DB0D267B99E Q24605618-7DDC9399-065A-46C2-9EED-2A876291F4BB Q27008959-C75F30F3-ED57-474F-AA7E-5F9B9F0CFEA2 Q27016541-8571ADB7-111D-41E8-8368-CEF4B115901F Q27022725-9EC8BBD6-7B73-4F25-8D74-83E135A7B908 Q30318110-54DCE5B8-28A8-4C09-B079-84F841AC388A Q33391089-FA1390C7-8493-4C57-9EB6-E77D620FE527 Q33405278-7069C8B5-AD0A-40C0-8C34-AA3BE66EAB0D Q33737884-33F0FB7C-3E04-4E76-BF77-6E1ACB6488D9 Q33772415-814E3DE1-74D4-40EB-9EEB-3DEEB6907335 Q33841417-24C3EFE5-2FA7-43FE-BA56-835918C30DD1 Q33850163-7DE25D01-9DB0-461B-8D26-E65FD3DE5887 Q33856972-24C1F654-3471-4033-9F41-6C9CFA9B7314 Q33903024-2E73951F-E677-4EC9-A23B-06A417F22A96 Q33985549-0EF7FA29-EEF7-4207-B78F-ACBEA5ACE001 Q34088403-7DD2BED5-84AC-49B2-A7B6-E6BD82FDDBC9 Q34172912-66129ED5-0EC2-4BD2-B230-DB7C9C8E814D Q34202277-33ED44E0-7809-4754-BE14-133966343C16 Q34258037-D437CD17-1B23-4F17-9514-A59A749A2F68 Q34630588-B0A80434-E864-4CF6-9D1B-F6570166F3BF Q34667390-8AF3652D-B57C-4CE0-A08D-54B220589C2C Q34667853-38D01C92-3ACD-40EA-A989-E2F35733130E Q34960346-F366DB43-056A-4CBD-ABB0-DA62039CC30E Q35591760-D02AFD68-BA81-4F32-AB46-C36BA430750C Q35772737-916FE4FA-50C9-455C-8237-CBD0EC7C8358 Q35825522-F3D97F27-B479-451C-9720-4DE08A7554F7 Q35835657-1A498B67-AC61-4703-87EE-FE23D3FDEA5D Q35854094-5E2539FB-CEAB-4DED-825F-90AF55466240 Q36055095-40C62D29-FE49-4112-8BC2-164A182514D6 Q36203084-CDF1B69F-A4DD-4E06-B5D0-90DCCC6297E6 Q36266642-9514FBD5-5FF4-4332-B1F3-2FCCCAE2C086 Q36506169-A02820D9-177D-46BC-8276-518A44568B46 Q36579060-1392FB38-3200-4592-AE36-FD8F47EE0B9B Q37344050-2719C6B4-2DCB-4F97-BD18-B51BD3FCD60A Q37416055-AABD7034-F76E-488F-8F7F-538AC4612CF1 Q37531039-DF69D685-2225-4F5A-9F46-A1F29B6758A5 Q37810125-37CDBCD5-BA72-4B23-AC1F-279DABE5D731 Q37942816-2C8DEA92-6F90-432B-8EE2-BD75A5D56F8C Q37962599-B9F85079-D755-4772-BB69-69E2765194D3 Q38095833-ABDFC4E9-BE31-401C-8F04-158477FC59CE

P2860

Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia

http://www.wikidata.org/entity/Q33861150

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia

@ast

Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia

@en

type

label

Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia

@ast

Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia

@en

prefLabel

Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia

@ast

Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia

@en

P1433

Q33861150-5EF898AA-6256-4895-89EF-D57327FE4F34

P1476

Q33861150-59B3EC7E-7B33-49C3-9646-6BE2AD23C73E

P2093

Q33861150-0F73536B-C2EB-4ECA-9723-21C1FB08AF80

Q33861150-6862381D-8913-44D1-985C-CDC2C4E4DF67

Q33861150-68683369-3247-4B46-AEE7-2B180AD41924

Q33861150-71653216-ED38-45CE-BEEF-6094F8B21B19

Q33861150-AD5766DA-D5B7-42DD-8F86-522FB815FA0B

Q33861150-C9900A4A-03A7-4C74-89FB-518446DFE45C

P2860

Q33861150-003B9943-D815-4233-B50B-B09EA38E3F56

Q33861150-326B68AE-6C7E-4878-99E6-167B6A7970C2

Q33861150-3EBB53FC-34A4-467F-AD5E-28226CBB36A2

Q33861150-5237C2C6-9185-4476-832E-096A96B92685

Q33861150-792BB934-41FB-4000-9F92-E55AD46E8B05

Q33861150-87129C06-C522-48A8-9505-283884FA9562

Q33861150-88DD7C75-F9C5-49F8-92C9-2749A1EB42FD

Q33861150-9C805A73-995C-4FB6-84E1-48471A5C8535

Q33861150-BC697308-4C2E-4B4A-A579-0EE7E8FB8D9A

Q33861150-CC0181A1-365A-4B8C-9280-FFDE082EFD62

P304

Q33861150-52979984-8209-455B-BF08-156B00DD2CA1

P31

Q33861150-E9A30BCF-CC3A-4F38-A7C3-E8206E54D494

P356

Q33861150-1D9A1F1E-FDA7-4CCF-9869-9BE2275E0868

P407

Q33861150-8DE693B7-084A-453C-A188-9FCA6457867C

P433

Q33861150-0D64122D-1B69-4FA8-8179-51ADD7394BCA

P478

Q33861150-0AAD06E9-B3D0-4972-B67D-22C90F919CC9

P50

Q33861150-31083AE0-2C84-4A34-90FF-635659BF4D1E

Q33861150-9A79075D-1932-4DAD-9F56-DAAA2B4B8549

Q33861150-BA46F511-12EE-4BB4-84CC-BC7AA2A0CE58

Q33861150-EDB5D834-8160-44EC-A208-6869DA81188E

P577

Q33861150-73FCA02F-BF96-4B17-B8C3-44F0BCF5B722

P5875

Q33861150-72CA1CBD-80FA-4B5F-8679-945FC0D2EB9E

P698

Q33861150-C233B7AE-C07A-4DB7-91F3-E4D8297187BD

P921

Q33861150-8540DDC0-2CE2-4E3F-ACD5-243CF1919ED6

P932

Q33861150-918489A8-727E-43B1-890F-56FD6A24AE23

P356

P1433

P1476

Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia

@en

P2093

Elizabeth J Shpall

http://www.w3.org/2001/XMLSchema#string

Leandro de Padua

http://www.w3.org/2001/XMLSchema#string

Madan Jagasia

http://www.w3.org/2001/XMLSchema#string

Marcos de Lima

http://www.w3.org/2001/XMLSchema#string

Partow Kebriaei

http://www.w3.org/2001/XMLSchema#string

Richard Champlin

http://www.w3.org/2001/XMLSchema#string

P2860

Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

5-Aza-2'-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends.

CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation.

Are new conditioning regimens for transplants in acute myelogenous leukemia better?

Induction of MHC class I-related chain B (MICB) by 5-aza-2'-deoxycytidine.

Graft-versus-leukemia reactions after bone marrow transplantation.

Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy.

Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2'-deoxycytidine.

P304

1899-1905

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.24198

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

Hagop Kantarjian

Guillermo Garcia-Manero

P577

2009-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24033024

http://www.w3.org/2001/XMLSchema#string

P698

19235255

http://www.w3.org/2001/XMLSchema#string

P921

P932

4086213

http://www.w3.org/2001/XMLSchema#string